K. V. Lenskaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
K. V. Lenskaya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- A. Yu. Petrov
Saint Petersburg State University
4 shared publications - Aleksey L. Kovalenko
Scientific Clinical Center of Toxicology named after Academician S.N. Golikov of the Federal Medical-Biological Agency
4 shared publications - Екатерина Владимировна Таликова
Saint Petersburg Medical and Social Institute
3 shared publications - M. I. Ivanova
Russian Medical Academy of Continuous Professional Education
2 shared publications - V. M. Ivanov
National Medical Research Treatment and Rehabilitation Centrer
2 shared publications - Denis Vladimirovich Kurkin
Russian University of Medicine. 2. Volgograd State Medical University
1 shared publication
Latest Publications
- 3 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 18 (6)
Correction of postoperative metabolic disorders after radiofrequency ablation for atrial fibrillation
Objective. To evaluate metabolic and neuroprotective properties of Cytoflavin in complex outpatient rehabilitation after radiofrequency ablation for atrial fibrillation. Material and methods. We analyzed the results of outpatient rehabilitation of 112 patients (50 men and 62 women, mean age 58.2±7.1 years) with paroxysmal atrial fibrillation after radiofrequency ablation. Patients were randomized into two groups: group I (main, n=59) — Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) prescribed in two-step scheme (20 ml intravenously in saline solution 200 ml for 10 days, then 2 tablets 2 times a day for 20 days); group II (comparison, n=53) — 10-day course of daily intravenous infusions of placebo 10 ml diluted in saline solution 200 ml followed by vitamin B12 (Vitamir) 1 tablet 1 time a day for 20 days. Cardiac parameters (echocardiography and ECG) and quality of life (HADS and MOS SF-36 questionnaires) were assessed before and after therapy. Results. Inclusion of Cytoflavin in outpatient rehabilitation therapy contributed to regression of ventricular hypertrophy (left by 1.2 times, right by 1.4 times) due to metabolic properties of this drug. Neuroprotective properties decreased anxiety by 5.3 times and depression by 1.7 times (HADS scale), as well as increased resistance to physical and emotional stress by 1.4 times (SF-36 scale). Conclusion. Inclusion of Cytoflavin in complex outpatient rehabilitation of patients with atrial fibrillation after radiofrequency ablation increases the effectiveness of treatment due to improvement of metabolic processes (reduction of atrial hypertrophy) and neuroprotective properties (reduction of anxiety and depression, increased resistance to physical and emotional stress). These data can be used for further studies.
- 3 December 2025
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 18 (6)
Correction of postoperative metabolic disorders after radiofrequency ablation for atrial fibrillation
Objective. To evaluate metabolic and neuroprotective properties of Cytoflavin in complex outpatient rehabilitation after radiofrequency ablation for atrial fibrillation. Material and methods. We analyzed the results of outpatient rehabilitation of 112 patients (50 men and 62 women, mean age 58.2±7.1 years) with paroxysmal atrial fibrillation after radiofrequency ablation. Patients were randomized into two groups: group I (main, n=59) — Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) prescribed in two-step scheme (20 ml intravenously in saline solution 200 ml for 10 days, then 2 tablets 2 times a day for 20 days); group II (comparison, n=53) — 10-day course of daily intravenous infusions of placebo 10 ml diluted in saline solution 200 ml followed by vitamin B12 (Vitamir) 1 tablet 1 time a day for 20 days. Cardiac parameters (echocardiography and ECG) and quality of life (HADS and MOS SF-36 questionnaires) were assessed before and after therapy. Results. Inclusion of Cytoflavin in outpatient rehabilitation therapy contributed to regression of ventricular hypertrophy (left by 1.2 times, right by 1.4 times) due to metabolic properties of this drug. Neuroprotective properties decreased anxiety by 5.3 times and depression by 1.7 times (HADS scale), as well as increased resistance to physical and emotional stress by 1.4 times (SF-36 scale). Conclusion. Inclusion of Cytoflavin in complex outpatient rehabilitation of patients with atrial fibrillation after radiofrequency ablation increases the effectiveness of treatment due to improvement of metabolic processes (reduction of atrial hypertrophy) and neuroprotective properties (reduction of anxiety and depression, increased resistance to physical and emotional stress). These data can be used for further studies.
- Open Access
- 11 November 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (7-8) , 41-46
Metabolic Therapy in Complex Rehabilitation of Patients After Radiofrequency Ablation
The aim of the study was to evaluate the effectiveness of including the drug cytoflavin in the complex rehabilitation of patients after radiofrequency catheter ablation. Material and methods . The results of outpatient treatment of 112 patients after radiofrequency ablation associated with paroxysmal atrial fibrillation were analyzed. The subjects were randomized into two groups: in group 1 (main, N=59), in addition to standard therapy, the drug Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) was prescribed according to a two-step regimen: 20.0 ml intravenously by drip in 200 ml of 0.9% sodium chloride solution for 10 days, then 2 tablets 2 times a day for 20 days. In the 2nd group (comparison, N=53), in addition to standard therapy, patients received a ten-day course of daily intravenous drip infusions of 10 ml of placebo diluted in 200.0 ml of 0.9% sodium chloride solution, followed by eleutherococcus extract 100 mg, 2 tablets 2 times a day before meals, and combination preparations of B vitamins in the dosage recommended by the manufacturer. The psychoemotional state of patients (using the Hospital Anxiety and Depression Scale (HADS)) and quality of life with a point assessment of subjective characteristics (using the multi-purpose MOS SF-36 questionnaire) were studied dynamically (before and after rehabilitation). Results. The inclusion of cytoflavin in the regimens contributed to a more significant reduction in the severity of anxiety compared to the patients in the control group — 5.3 times, while in the control group the reduction amounted to only 1.75 times (P˂0.05), and signs of depression — 2 and 1.5 times, respectively (P˂0.05). The effectiveness of the presented outpatient treatment regimen was confirmed by the positive dynamics of patients' quality of life indicators on all SF-36 scales: the initial level of physical health of patients in group 1 increased from 69.8±13.2 to 85.6±4.2 (P˂0.05), and mental health — from 62.3±8.4 to 78.4±3.2 (P˂0.05), while in the comparison group — from 68.7±13.4 to 81.2±3.2 (P˂0.05) and from 61.4±7.3 to 71.3±2.2 (P˂0.05), respectively. Conclusion. The study showns the effectiveness of using Cytoflavin in the early restorative treatment of patients after radiofrequency catheter ablation, which is manifested by a more pronounced improvement in the psychoemotional state and quality of life of these patients.
- 11 November 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (7-8) , 41-46
Open AccessMetabolic Therapy in Complex Rehabilitation of Patients After Radiofrequency Ablation
The aim of the study was to evaluate the effectiveness of including the drug cytoflavin in the complex rehabilitation of patients after radiofrequency catheter ablation. Material and methods . The results of outpatient treatment of 112 patients after radiofrequency ablation associated with paroxysmal atrial fibrillation were analyzed. The subjects were randomized into two groups: in group 1 (main, N=59), in addition to standard therapy, the drug Cytoflavin (inosine+nicotinamide+riboflavin+succinic acid) was prescribed according to a two-step regimen: 20.0 ml intravenously by drip in 200 ml of 0.9% sodium chloride solution for 10 days, then 2 tablets 2 times a day for 20 days. In the 2nd group (comparison, N=53), in addition to standard therapy, patients received a ten-day course of daily intravenous drip infusions of 10 ml of placebo diluted in 200.0 ml of 0.9% sodium chloride solution, followed by eleutherococcus extract 100 mg, 2 tablets 2 times a day before meals, and combination preparations of B vitamins in the dosage recommended by the manufacturer. The psychoemotional state of patients (using the Hospital Anxiety and Depression Scale (HADS)) and quality of life with a point assessment of subjective characteristics (using the multi-purpose MOS SF-36 questionnaire) were studied dynamically (before and after rehabilitation). Results. The inclusion of cytoflavin in the regimens contributed to a more significant reduction in the severity of anxiety compared to the patients in the control group — 5.3 times, while in the control group the reduction amounted to only 1.75 times (P˂0.05), and signs of depression — 2 and 1.5 times, respectively (P˂0.05). The effectiveness of the presented outpatient treatment regimen was confirmed by the positive dynamics of patients' quality of life indicators on all SF-36 scales: the initial level of physical health of patients in group 1 increased from 69.8±13.2 to 85.6±4.2 (P˂0.05), and mental health — from 62.3±8.4 to 78.4±3.2 (P˂0.05), while in the comparison group — from 68.7±13.4 to 81.2±3.2 (P˂0.05) and from 61.4±7.3 to 71.3±2.2 (P˂0.05), respectively. Conclusion. The study showns the effectiveness of using Cytoflavin in the early restorative treatment of patients after radiofrequency catheter ablation, which is manifested by a more pronounced improvement in the psychoemotional state and quality of life of these patients.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 85-95
Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke
Objective. To compare the neuroprotective effects of Cytoflavine (CF) and citicoline (CC) in a rat model of hemorrhagic stroke (HS). Material and methods. The study was conducted on male Wistar rats. HS was induced by the injecting of autologous blood into brain tissue. Drugs CF and CC were administered in parenteral (10 days) and oral (25 days) forms. The experiment concluded with a 14-day post-treatment period. Neurological deficits were assessed after each treatment period, and brain tissue edema was measured immediately after the completion of both parenteral and oral treatments and again after 14 days of drug discontinuation. A series limited to a 10-day intravenous treatment with CF was created to compare the efficacy of single and combined treatment regimens. Results. HS stroke led to the development of significant neurological deficits. The greatest improvement was observed in the groups receiving oral treatments with CF and CC, which demonstrated pronounced neuroprotective effects and accelerated recovery of impaired functions, with some differences between the groups. The 10-day intravenous administration of CF and CC resulted in a comparable significant reduction in the severity of neurological deficits related to sensorimotor dysfunction. However, substantial recovery of cognitive function required continuation of oral treatment for 25 days. At the end of the oral treatment phase, edema severity in the affected hemisphere was comparable between both groups and significantly lower than in the placebo group. The therapeutic effect of CF (in terms of neurological deficit and brain tissue edema), in a combined administration regimen, persisted 14 days after discontinuation of treatment, in contrast to CC. In an additional series, where CF treatment was limited to a 10-day intravenous course, the anti-edema effect did not remain significant after the 14-day treatment cessation, with notable differences from the untreated group observed only in motor activity levels. Conclusion. The comparative study of the neuroprotective effects of CF and CC in a rat model of HS revealed that both drugs significantly reduced brain edema and neurological deficits related to sensorimotor and cognitive impairments. CC showed a slight psychostimulatory effect and a shorter duration of action after treatment cessation, while CF exhibited a longer-lasting effect on brain tissue edema, cognitive, and sensorimotor functions after discontinuation. The separate series with only 10-day intravenous CF administration was insufficient to achieve a stable therapeutic effect, suggesting that the continuation of CF treatment with oral forms is required to maintain long-term benefits in the context of experimental HS in rats.
- 29 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 85-95
Comparative study of the neuroprotective effects of the drug Cytoflavin and citicoline in a rats model of hemorrhagic stroke
Objective. To compare the neuroprotective effects of Cytoflavine (CF) and citicoline (CC) in a rat model of hemorrhagic stroke (HS). Material and methods. The study was conducted on male Wistar rats. HS was induced by the injecting of autologous blood into brain tissue. Drugs CF and CC were administered in parenteral (10 days) and oral (25 days) forms. The experiment concluded with a 14-day post-treatment period. Neurological deficits were assessed after each treatment period, and brain tissue edema was measured immediately after the completion of both parenteral and oral treatments and again after 14 days of drug discontinuation. A series limited to a 10-day intravenous treatment with CF was created to compare the efficacy of single and combined treatment regimens. Results. HS stroke led to the development of significant neurological deficits. The greatest improvement was observed in the groups receiving oral treatments with CF and CC, which demonstrated pronounced neuroprotective effects and accelerated recovery of impaired functions, with some differences between the groups. The 10-day intravenous administration of CF and CC resulted in a comparable significant reduction in the severity of neurological deficits related to sensorimotor dysfunction. However, substantial recovery of cognitive function required continuation of oral treatment for 25 days. At the end of the oral treatment phase, edema severity in the affected hemisphere was comparable between both groups and significantly lower than in the placebo group. The therapeutic effect of CF (in terms of neurological deficit and brain tissue edema), in a combined administration regimen, persisted 14 days after discontinuation of treatment, in contrast to CC. In an additional series, where CF treatment was limited to a 10-day intravenous course, the anti-edema effect did not remain significant after the 14-day treatment cessation, with notable differences from the untreated group observed only in motor activity levels. Conclusion. The comparative study of the neuroprotective effects of CF and CC in a rat model of HS revealed that both drugs significantly reduced brain edema and neurological deficits related to sensorimotor and cognitive impairments. CC showed a slight psychostimulatory effect and a shorter duration of action after treatment cessation, while CF exhibited a longer-lasting effect on brain tissue edema, cognitive, and sensorimotor functions after discontinuation. The separate series with only 10-day intravenous CF administration was insufficient to achieve a stable therapeutic effect, suggesting that the continuation of CF treatment with oral forms is required to maintain long-term benefits in the context of experimental HS in rats.
- Open Access
- 6 August 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (3-4) , 55-59
The Role of Hepatoprotection in the Treatment of Pulmonary Tuberculosis Comorbid with HIV Infection and Chronic Viral Hepatitis
The increase in the proportion of comorbid forms of socially significant infections, in particular the combination of tuberculosis with HIV infection and chronic viral hepatitis, is a pressing problem, including of a therapeutic nature: on the one hand, the combined use of anti-tuberculosis and antiretroviral therapy creates an additional burden on the liver; on the other hand, the situation is aggravated by specific disorders of its function associated with the presence of a chronic viral infection, most often hepatitis C and B. In this regard, the inclusion of drugs with hepatoprotective properties in the treatment regimens for this pathology is advisable. The article presents a clinical observation of the effectiveness of remaxol inclusion in the treatment regimen of a patient with disseminated pulmonary tuberculosis, comorbid with HIV infection and chronic hepatitis C with signs of a hepatotoxic reaction to the etiotropic therapy (the main course of treatment). The drug was administered according to the scheme: 400.0 ml intravenously by drip every other day No. 5, then 400.0 intravenously by drip once a week No. 4. The treatment with remaxol contributed to the relief of clinical and laboratory signs of drug-induced liver damage, which in turn made it possible not to interrupt the course of etiotropic therapy, while the improvement of the general condition of the patient increased his adherence to the treatment. The obtained results allow us to continue research in this direction.
- 6 August 2025
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 70 (3-4) , 55-59
Open AccessThe Role of Hepatoprotection in the Treatment of Pulmonary Tuberculosis Comorbid with HIV Infection and Chronic Viral Hepatitis
The increase in the proportion of comorbid forms of socially significant infections, in particular the combination of tuberculosis with HIV infection and chronic viral hepatitis, is a pressing problem, including of a therapeutic nature: on the one hand, the combined use of anti-tuberculosis and antiretroviral therapy creates an additional burden on the liver; on the other hand, the situation is aggravated by specific disorders of its function associated with the presence of a chronic viral infection, most often hepatitis C and B. In this regard, the inclusion of drugs with hepatoprotective properties in the treatment regimens for this pathology is advisable. The article presents a clinical observation of the effectiveness of remaxol inclusion in the treatment regimen of a patient with disseminated pulmonary tuberculosis, comorbid with HIV infection and chronic hepatitis C with signs of a hepatotoxic reaction to the etiotropic therapy (the main course of treatment). The drug was administered according to the scheme: 400.0 ml intravenously by drip every other day No. 5, then 400.0 intravenously by drip once a week No. 4. The treatment with remaxol contributed to the relief of clinical and laboratory signs of drug-induced liver damage, which in turn made it possible not to interrupt the course of etiotropic therapy, while the improvement of the general condition of the patient increased his adherence to the treatment. The obtained results allow us to continue research in this direction.